PROJECT: CLINICAL GUIDELINES FOR THE DIAGNOSTICS AND TREATMENT OF ULCERATIVE COLITIS

<jats:p>.</jats:p>

[1]  K. Hennessey,et al.  Effective Dosage of Oral Vancomycin in Treatment for Initial Episode of Clostridioides difficile Infection: A Systematic Review and Meta-Analysis , 2019, Antibiotics.

[2]  Samir A. Shah,et al.  Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort , 2019, BMC Gastroenterology.

[3]  L. Simms,et al.  Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn’s Disease , 2018, Digestive Diseases and Sciences.

[4]  A. O. Golovenko,et al.  Social and demographic characteristics, features of disease course and treatment options of inflammatory bowel disease in Russia: results of two multicenter studies , 2018, Almanac of Clinical Medicine.

[5]  S. Feng,et al.  CT Enterography score: a potential predictor for severity assessment of active ulcerative colitis , 2018, BMC Gastroenterology.

[6]  S. Bonovas,et al.  Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. , 2018, Inflammatory bowel diseases.

[7]  W. Kassem,et al.  Outcome of Cytomegalovirus Colitis in Inflammatory Bowel Disease with Different Regimes of Ganciclovir , 2018, Middle East journal of digestive diseases.

[8]  B. Sands,et al.  DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open , 2018 .

[9]  Jing Liu,et al.  Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Crohn's Disease , 2017, Gastroenterology research and practice.

[10]  G. D'Haens.  Systematic review: second‐generation vs. conventional corticosteroids for induction of remission in ulcerative colitis , 2016, Alimentary pharmacology & therapeutics.

[11]  G. D'Haens,et al.  Acute severe ulcerative colitis: from pathophysiology to clinical management , 2016, Nature Reviews Gastroenterology &Hepatology.

[12]  S. Tschudin-Sutter,et al.  Growth Patterns of Clostridium difficile – Correlations with Strains, Binary Toxin and Disease Severity: A Prospective Cohort Study , 2016, PloS one.

[13]  I. Lawrance,et al.  Acute Severe Ulcerative Colitis: Evidence Based Consensus Statements , 2017 .

[14]  P. De Cruz,et al.  Review article: the practical management of acute severe ulcerative colitis , 2016, Alimentary pharmacology & therapeutics.

[15]  P. Rutgeerts,et al.  Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. , 2016, Gastroenterology.

[16]  C. Hagiu,et al.  Non-Invasive Assessment of Inflammation and Treatment Response in Patients with Crohn's Disease and Ulcerative Colitis using Contrast-Enhanced Ultrasonography Quantification. , 2015, Journal of gastrointestinal and liver diseases : JGLD.

[17]  G. Lichtenstein.  Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis , 2015, Digestive Diseases and Sciences.

[18]  V. Anttila,et al.  Highlighting clinical needs in Clostridium difficile infection: the views of European healthcare professionals at the front line. , 2015, The Journal of hospital infection.

[19]  J. Gisbert,et al.  European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. , 2015, Journal of Crohn's & colitis.

[20]  N. Ba,et al.  [Long-term results of medical treatment in patients with a severe attack of ulcerative colitis]. , 2015 .

[21]  P. Lakatos,et al.  Ulcerative proctitis: an update on the pharmacotherapy and management , 2014, Expert opinion on pharmacotherapy.

[22]  C. Siegel,et al.  Review article: integrating budesonide‐MMX into treatment algorithms for mild‐to‐moderate ulcerative colitis , 2014, Alimentary pharmacology & therapeutics.

[23]  A. Gasbarrini,et al.  Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. , 2014, Journal of Crohn's & colitis.

[24]  P. Rutgeerts,et al.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. , 2014, Gastroenterology.

[25]  P. Rutgeerts,et al.  Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[26]  P. Rutgeerts,et al.  Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[27]  S. Miszputen,et al.  Anemia in inflammatory bowel disease: prevalence, differential diagnosis and association with clinical and laboratory variables. , 2014, Sao Paulo medical journal = Revista paulista de medicina.

[28]  A. Amiot,et al.  European evidence based consensus for endoscopy in inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.

[29]  T. Kim,et al.  Correlations of C-reactive Protein Levels and Erythrocyte Sedimentation Rates with Endoscopic Activity Indices in Patients with Ulcerative Colitis , 2013, Digestive Diseases and Sciences.

[30]  Zhiping Yang,et al.  Meta‐analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery , 2012, Alimentary pharmacology & therapeutics.

[31]  B. Feagan,et al.  Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta‐analysis , 2012, Inflammatory bowel diseases.

[32]  A. Larsson,et al.  Ruling out IBD: estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. , 2012, Clinical biochemistry.

[33]  P. Rutgeerts,et al.  Long‐term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT‐1 and ‐2 Extension Studies , 2012, Inflammatory bowel diseases.

[34]  P. Moayyedi,et al.  Efficacy of Oral vs. Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Meta-Analysis , 2012, The American Journal of Gastroenterology.

[35]  B. Warner,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[36]  R. Jenaw,et al.  Effectiveness of plain radiography in diagnosing hollow viscus perforation: study of 1,723 patients of perforation peritonitis , 2012, Emergency Radiology.

[37]  Philippe Seksik,et al.  Epidemiology and natural history of inflammatory bowel diseases. , 2011, Gastroenterology.

[38]  P. Moayyedi,et al.  Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[39]  P. Moayyedi,et al.  Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[40]  A. Darzi,et al.  Volume analysis of outcome following restorative proctocolectomy , 2011, The British journal of surgery.

[41]  E. Weiss,et al.  Ileal pouch–anal anastomosis in elderly patients: is there a difference in morbidity compared with younger patients? , 2011, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[42]  B. Flourié,et al.  A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization , 2010, The American Journal of Gastroenterology.

[43]  H. Sokol,et al.  Risk Factors for Neoplasia in Inflammatory Bowel Disease Patients With Pancolitis , 2010, The American Journal of Gastroenterology.

[44]  H. Tajiri,et al.  What's Hot in the Red Journal This Month? , 2010, The American Journal of Gastroenterology.

[45]  M. Lamet.  A Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Mesalamine Suppositories 1 g at Bedtime and 500 mg Twice Daily in Patients with Active Mild-to-Moderate Ulcerative Proctitis , 2010, Digestive Diseases and Sciences.

[46]  F. Carrat,et al.  Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy , 2010, Gut.

[47]  P. Gaburri,et al.  Azathioprine maintains long‐term steroid‐free remission through 3 years in patients with steroid‐dependent ulcerative colitis† , 2010, Inflammatory bowel diseases.

[48]  B. Warren,et al.  Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications , 2010, The British journal of surgery.

[49]  L. Laine,et al.  Cytomegalovirus Infection in Patients with Active Inflammatory Bowel Disease , 2010, Digestive Diseases and Sciences.

[50]  P. Ciclitira,et al.  Guide to endoscopy of the ileo‐anal pouch following restorative proctocolectomy with ileal pouch‐anal anastomosis; indications, technique, and management of common findings , 2009, Inflammatory bowel diseases.

[51]  P. Rutgeerts,et al.  Corticosteroids but not infliximab increase short‐term postoperative infectious complications in patients with ulcerative colitis , 2009, Inflammatory bowel diseases.

[52]  J. Mate,et al.  Meta‐analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis , 2009, Alimentary pharmacology & therapeutics.

[53]  A. Ananthakrishnan,et al.  Clostridium difficile and inflammatory bowel disease. , 2008, Inflammatory bowel diseases.

[54]  Y. Arbel,et al.  Comparative analysis of Bayer wide‐range C‐reactive protein (wr‐CRP) and the Dade‐Behring high sensitivity C‐reactive protein (hs‐CRP) in patients with inflammatory bowel disease , 2008, Journal of digestive diseases.

[55]  G. Kaplan,et al.  A National Survey of the Prevalence and Impact of Clostridium difficile Infection Among Hospitalized Inflammatory Bowel Disease Patients , 2008, The American Journal of Gastroenterology.

[56]  W. Cacheux,et al.  Predictive Factors of Response to Cyclosporine in Steroid-Refractory Ulcerative Colitis , 2008, The American Journal of Gastroenterology.

[57]  C. Lees,et al.  A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis , 2007, Alimentary pharmacology & therapeutics.

[58]  M. Vatn,et al.  Dysplasia and Cancer in Inflammatory Bowel Disease 10 Years after Diagnosis: Results of a Population-Based European Collaborative Follow-Up Study , 2007, Digestion.

[59]  Y. Panis,et al.  Laparoscopic subtotal colectomy for acute or severe colitis complicating inflammatory bowel disease: a case-matched study in 88 patients. , 2007, Surgery.

[60]  Kimberly A. Reske,et al.  Incidence of Clostridium difficile infection in inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[61]  Dawn B. Beaulieu,et al.  Impact of Clostridium difficile on inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[62]  Konstantinos H. Katsanos,et al.  Predictors of early response to infliximab in patients with ulcerative colitis , 2007, Inflammatory bowel diseases.

[63]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[64]  R. Beart,et al.  Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch–anal anastomosis , 2004, Journal of Gastrointestinal Surgery.

[65]  A. Griffiths,et al.  Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[66]  S. Galandiuk,et al.  Smoking and inflammatory bowel disease: a meta-analysis. , 2006, Mayo Clinic proceedings.

[67]  H. Steinhart,et al.  Medical management of left‐sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials , 2006, Inflammatory bowel diseases.

[68]  S. Vermeire.  Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease , 2006, Alimentary pharmacology & therapeutics.

[69]  R. Pollok,et al.  Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators , 2006, The British journal of surgery.

[70]  L. Melton,et al.  Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. , 2006, Gastroenterology.

[71]  G. Porro,et al.  A rare cause of diuretic refractory ascites , 2005, Gut.

[72]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[73]  Å. Danielsson,et al.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.

[74]  D. Larson,et al.  Ileal pouch-anal anastomosis: does age at the time of surgery affect outcome? , 2005, Archives of surgery.

[75]  H. Järvinen,et al.  Fate of the Rectum after Colectomy with Ileorectal Anastomosis in Ulcerative Colitis , 2005, Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.

[76]  Feza H. Remzi,et al.  Evaluation of the Learning Curve in Ileal Pouch–Anal Anastomosis Surgery , 2005, Annals of surgery.

[77]  N. Hyman,et al.  Urgent Subtotal Colectomy for Severe Inflammatory Bowel Disease , 2005, Diseases of the colon and rectum.

[78]  L. Tanoue,et al.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. , 2005, American journal of respiratory and critical care medicine.

[79]  D. Symmons,et al.  Systematic review: is ingestion of paracetamol or non‐steroidal anti‐inflammatory drugs associated with exacerbations of inflammatory bowel disease? , 2004, Alimentary pharmacology & therapeutics.

[80]  S. Travis,et al.  Guidelines for the management of inflammatory bowel disease in adults , 2004, Gut.

[81]  V. Medici,et al.  Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[82]  Z. Cohen,et al.  Female Infertility After Ileal Pouch-Anal Anastomosis for Ulcerative Colitis , 2004, Diseases of the colon and rectum.

[83]  B. Sands.  From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. , 2004, Gastroenterology.

[84]  Alastair Forbes,et al.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. , 2004, Gastroenterology.

[85]  S. Gallus,et al.  Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel , 2003, Alimentary pharmacology & therapeutics.

[86]  P. Beck,et al.  A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management , 2003, American Journal of Gastroenterology.

[87]  T. Öresland,et al.  Quality of life before and after proctocolectomy and IPAA in patients with ulcerative proctocolitis – a prospective study , 2003, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[88]  A. Zinsmeister,et al.  Azathioprine or 6-Mercaptopurine Before Colectomy for Ulcerative Colitis Is Not Associated With Increased Postoperative Complications , 2002, Inflammatory bowel diseases.

[89]  J. Church,et al.  Functional Outcome, Quality of Life, and Complications After Ileal Pouch-Anal Anastomosis in Selected Septuagenarians , 2002, Diseases of the colon and rectum.

[90]  J. Achkar,et al.  Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis , 2002, American Journal of Gastroenterology.

[91]  S. Laurberg,et al.  Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. , 2002, Gastroenterology.

[92]  D. Richards,et al.  Patient quality of life after successful restorative proctocolectomy is normal , 2001, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[93]  E. Parlak,et al.  Comparison of 5-amino salicylic acid plus glucocorticosteroid with metronidazole and ciprofloxacin in patients with active ulcerative colitis. , 2001, Journal of clinical gastroenterology.

[94]  K. Abrams,et al.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis , 2001, Gut.

[95]  J. Church.  Functional outcome and quality of life in an elderly patient with an ileal pouch-anal anastomosis: a 10-year follow up. , 2000, The Australian and New Zealand journal of surgery.

[96]  R. Thirlby,et al.  Risk Factors and True Incidence of Pouchitis in Patients after Ileal Pouch–Anal Anastomoses , 2000, World Journal of Surgery.

[97]  M. Tanaka, H. Saito, S. Fukuda, Y. Sasaki, A. Muna,et al.  Simple Mucosal Biopsy Criteria Differentiating among Crohn Disease, Ulcerative Colitis, and Other Forms of Colitis: Measurement of Validity , 2000 .

[98]  C. M. Edwards,et al.  Diversion colitis: new light through old windows , 1999, Histopathology.

[99]  S. Laurberg,et al.  Fertility after ileal pouch–anal anastomosis in women with ulcerative colitis , 1999, The British journal of surgery.

[100]  K. Zimmer,et al.  Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. , 1999, Journal of pediatric gastroenterology and nutrition.

[101]  R. Löfberg,et al.  Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis , 1998, European journal of gastroenterology & hepatology.

[102]  R. Farouk,et al.  J ileal pouch–anal anastomosis for chronic ulcerative colitis: complications and long‐term outcome in 1310 patients , 1998, The British journal of surgery.

[103]  I. Talbot,et al.  Patterns of distribution of endoscopic and histological changes in the ileal reservoir after restorative proctocolectomy for ulcerative colitis A long-term follow-up study , 1998, International Journal of Colorectal Disease.

[104]  J. Marshall,et al.  Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. , 1997, Gut.

[105]  P. Sagar,et al.  Ileo-anal pouch function and dysfunction. , 1997, Digestive diseases.

[106]  D. Jewell,et al.  Predicting outcome in severe ulcerative colitis. , 1996, Gut.

[107]  J. Church,et al.  IIeal Pouch‐Anal Anastomoses Complications and Function in 1005 Patients , 1995, Annals of surgery.

[108]  J. Ritchie,et al.  The first 10 years' experience of restorative proctocolectomy for ulcerative colitis. , 1994, Gut.

[109]  B. Nordlinger,et al.  Function of ileal J pouch‐anal anastomosis in patients with familial adenomatous polyposis , 1993, The British journal of surgery.

[110]  J. Murray,et al.  Long-term results of the ileoanal pouch procedure. , 1993, Archives of surgery.

[111]  Å. Danielsson,et al.  A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. , 1992, Scandinavian journal of gastroenterology.

[112]  B C Morson,et al.  Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. , 1987, Journal of clinical pathology.

[113]  C. Spicer,et al.  Assessment of severity in colitis: a preliminary study. , 1975, Gut.

[114]  C. Clark,et al.  The absorption and secretion of water and electrolytes across the healthy and the diseased human colonic mucosa measured in vitro , 1972, Gut.

[115]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .